Could antibodies against Serum Amyloid A function as physiological regulators in humans?

References

• Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999; 340:448–454.
   PubMed Web of Science ®Google Scholar
• Kravitz MS, Pitashny M, Shoenfeld Y. Protective molecules–C-reactive protein (CRP), serum amyloid P (SAP), pentraxin3 (PTX3), mannose-binding lectin (MBL), and apolipoprotein A1 (Apo A1), and their autoantibodies: Prevalence and clinical significance in autoimmunity. J Clin Immunol. 2005; 25:582–591.
   PubMed Web of Science ®Google Scholar
• Malle E. De Beer FC. Human serum amyloid A (SAA) protein: A prominent acute-phase reactant for clinical practice. Eur J Clin Invest. 1996; 264:7–35.
   Google Scholar
• Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem. 199923.
   Google Scholar
• Kaplan B, Yakar S, Balta Y, Pras M, Martin B. Isolation and purification of two major serum amyloid A isotypes SAA1 and SAA2 from the acute phase plasma of mice. J Chromatogr B Biomed Sci Appl. 1997; 704:69–76.
   PubMedGoogle Scholar
• Steel DM, Whitehead AS. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunol Today. 1994; 15:81–88.
   PubMedGoogle Scholar
• Johnson BD, Kip KE, Marroquin OC, Ridker PM, Kelsey SF, Shaw LJ, Pepine CJ, Sharaf B, Bairey Merz CN, Sopko G, Olson MB, Reis SE. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: The National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation. 2004; 109:726–732.
   PubMed Web of Science ®Google Scholar
• Katayama T, Nakashima H, Takagi C, Honda Y, Suzuki S, Iwasaki Y, Yano K. Prognostic value of serum amyloid A protein in patients with acute myocardial infarction. Circ J. 2005; 69:1186–1191.
   PubMedGoogle Scholar
• Malle E, Sodin-Semrl S, Kovacevic A. Serum amyloid A: An acute-phase protein involved in tumour pathogenesis. Cell Mol Life Sci. 2009; 66:9–26.
   PubMedGoogle Scholar
• Cunnane G, Grehan S, Geoghegan S, McCormack C, Shields D, Whitehead AS, Bresnihan B, Fitzgerald O. Serum amyloid A in the assessment of early inflammatory arthritis. J Rheumatol. 2000; 27:58–63.
   PubMed Web of Science ®Google Scholar
• Watson G, See CG, Woo P. Use of somatic cell hybrids and fluorescence in situ hybridization to localize the functional serum amyloid A (SAA) genes to chromosome 11p15.4-p15.1 and the entire SAA superfamily to chromosome 11p15. Genomics. 1994; 23:694–696.
   PubMed Web of Science ®Google Scholar
• Upragarin N, Landman WJ, Gaastra W, Gruys E. Extrahepatic production of acute phase serum amyloid A. Histol Histopathol. 2005; 20:1295–1307.
   PubMed Web of Science ®Google Scholar
• Uhlar CM, Whitehead AS. The kinetics and magnitude of the synergistic activation of the serum amyloid A promoter by IL-1 beta and IL-6 is determined by the order of cytokine addition. Scand J Immunol. 1999; 49:399–404.
   PubMed Web of Science ®Google Scholar
• Patel H, Fellowes R, Coade S, Woo P. Human serum amyloid A has cytokine-like properties. Scand J Immunol. 1998; 48:410–418.
   PubMed Web of Science ®Google Scholar
• van der Westhuyzen DR, Cai L, de Beer MC, de Beer FC. Serum amyloid A promotes cholesterol efflux mediated by scavenger receptor B-I. Biol Chem. 2005; 280:35890–35895.
   Web of Science ®Google Scholar
• Rosenau BJ, Schur PH. Antibody to serum amyloid A. J Autoimmun. 2004; 23:179–182.
   PubMed Web of Science ®Google Scholar
• Shoenfeld Y, Twig G, Katz U, Sherer Y. Autoantibody explosion in antiphospholipid syndrome. J Autoimmun. 2008; 30:74–83.
   PubMed Web of Science ®Google Scholar
• Sherer Y, Gorstein A, Fritzler MJ, Shoenfeld Y. Autoantibody explosion in systemic lupus erythematosus: More than 100 different antibodies found in SLE patients. Semin Arthritis Rheum. 2004; 34:501–537.
   PubMed Web of Science ®Google Scholar
• Lutz HU. Homeostatic roles of naturally occurring antibodies: An overview. J Autoimmun. 2007; 29:287–294.
   PubMed Web of Science ®Google Scholar
• Poletaev A, Osipenko L. General network of natural autoantibodies as immunological homunculus. Autoimm Rev. 2003; 2:264–271.
   PubMed Web of Science ®Google Scholar
• Tsonis IA, Avrameas S, Moutsopoulos HM. Autoimmunity and pathphysiology. J Autoimmun. 2007; 29:203–205.
   PubMed Web of Science ®Google Scholar
• Cohen IR. Biomarkers, self-antigens and the immunological homunculus. J Autoimmun. 2007; 29:246–249.
   PubMed Web of Science ®Google Scholar
• Poletaev AB, Stepanyuk VL, Gershwin ME. Integrating immunity: The immunculus and self-reactivity. J Autoimmun. 2008; 30:68–73.
   PubMed Web of Science ®Google Scholar
• Jerne NK. Towards a network theory of the immune system. Ann Immunol (Inst Pasteur). 1974; 125:373–389.
   Google Scholar
• Cohen IR, Young DB. Autoimmunity, microbial immunity and the immunological homunculus. Immunol Today. 1991; 12:105–110.
   PubMedGoogle Scholar
• Bendtzen K, Svenson M, Jonsson V, Hippe E. Autoantibodies to cytokines-friends or foes?. Immunol Today. 1990; 11:167–169.
   PubMedGoogle Scholar
• Vollmers HP, Brandlein S. Natural antibodies and cancer. J Autoimmun. 2007; 29:295–302.
   PubMed Web of Science ®Google Scholar
• Casali P, Notkins AL. CD5+ B-lymphocytes, polyreactive antibodies and the human B-cell repertoire. Immunol Today. 1989; 10:364–368.
   PubMedGoogle Scholar
• Szabo P, Relkin N, Weksler ME. Natural human antibodies to amyloid beta peptide. Autoimmun Rev. 2008; 7:415–420.
   PubMed Web of Science ®Google Scholar
• Geylis V, Steinitz M. Immunotherapy of Alzheimer's disease (AD): From murine models to anti-amyloid beta (Abeta) human monoclonal antibodies. Autoimmun Rev. 2006; 5:33–39.
   PubMed Web of Science ®Google Scholar
• Omersel J, Jurgec I, Cucnik S, Kveder T, Rozman B, Sodin-Semrl S, Bozic B. Autoimmune and proinflammatory activity of oxidized immunoglobulins. Autoimmun Rev. 2008; 7:523–529.
   PubMed Web of Science ®Google Scholar
• McIntyre JA, Wagenknecht DR, Ramsey CJ. Redox-reactive antiphospholipid antibody differences between serum from Alzheimer's patients and age-matched controls. Autoimmunity. 2009; 42:646–652.
   PubMed Web of Science ®Google Scholar
• Rosenau BJ, Schur PH. Autoantibodies to tumor necrosis factor in patients with rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol. 2009; 36:753–756.
   PubMedGoogle Scholar
• Sodin-Semrl S, Zigon P, Cucnik S, Kveder T, Blinc A, Tomsic M, Rozman B. Serum amyloid A in autoimmune thrombosis. Autoimmun Rev. 2006; 6:21–27.
   PubMed Web of Science ®Google Scholar
• Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4:295–306.
   PubMed Web of Science ®Google Scholar
• Bozic B, Cucnik S, Kveder T, Rozman B. 2007. Affinity and avidity of autoantibodies. In: Schoenfeld Y, Gershwin ME, Meroni PL. editors. Autoantibodies. Burlington, MA: Elsevier BV. p 21–35.
   Google Scholar
• R Development Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing Available at: http://www.R-project.org 2009.
   Google Scholar
• Royston P. An extension of Shapiro and Wilk's W test for normality to large samples. Appl Stat. 1982; 31:115–124.
   Web of Science ®Google Scholar
• Malle E, Herz R, Artl A, Ibovnik A, Andreae F, Sattler W. Mapping of antigenic determinants of purified, lipid-free human serum amyloid A proteins. Scand J Immunol. 1998; 48:557–561.
   PubMed Web of Science ®Google Scholar
• Kravitz MS, Shoenfeld Y. Autoimmunity to protective molecules: Is it the perpetuum mobile (vicious cycle) of autoimmune rheumatic diseases?. Nat Clin Pract Rheumatol. 2006; 2:481–490.
   PubMedGoogle Scholar
• Wang L, Colón W. Urea-induced denaturation of apolipoprotein serum amyloid A reveals marginal stability of hexamer. Protein Sci. 2005; 14:1811–1817.
   PubMed Web of Science ®Google Scholar
• Huflejt ME, Vuskovic M, Vasiliu D, Xu H, Obukhova P, Shilova N, Tuzikov A, Galanina O, Arun B, Lu K, Bovin N. Anti-carbohydrate antibodies of normal sera: Findings, surprises and challenges. Mol Immunol. 2009; 46:3037–3049.
   PubMed Web of Science ®Google Scholar
• Evans M, Abdou NI. Anti-interleukin-6 and soluble interleukin-6 receptor in systemic lupus erythematosus. Lupus. 1994; 3:161–166.
   PubMed Web of Science ®Google Scholar
• Sjowall C, Ernerudh J, Bengtsson AA, Sturfelt G, Skogh T. Reduced anti-TNFα autoantibody levels coincide with flare in systemic lupus erythematosus. J Autoimmun. 2004; 22:315–323.
   PubMed Web of Science ®Google Scholar
• Wettero J, Nilsson L, Jonasson L, Sjowall C. Reduced serum levels of autoantibodies against monomeric C-reactive protein (CRP) in patients with acute coronary syndrome. Clin Chim Acta. 2009; 400:128–131.
   PubMed Web of Science ®Google Scholar
• Ross C, Svenson M, Nielsen H, Lundsgaard C, Hansen MB, Bendtzen K. Increased in vivo antibody activity against interferon alpha, interleukin-1alpha, and interleukin-6 after high-dose IVIG therapy. Blood. 1997; 90:2376–2380.
   PubMed Web of Science ®Google Scholar
• Jouvenne P, Fossiez F, Banchereau J, Miossec P. High levels of neutralizing autoantibodies against IL-1 alpha are associated with a better prognosis in chronic polyarthritis: A follow-up study. Scand J Immunol. 1997; 46:413–418.
   PubMed Web of Science ®Google Scholar
• Marhaug G, Dowton SB. Serum amyloid A: An acute phase apolipoprotein and precursor of AA amyloid. Baillieres Clin Rheumatol. 1994; 8:553–573.
   PubMedGoogle Scholar
• Neureiter D, Heuschmann P, Stintzing S, Kolominsky-Rabas P, Barbera L, Jung A, Ocker M, Maass M, Faller G, Kirchner T. Detection of Chlamydia pneumoniae but not of Helicobacter pylori in symptomatic atherosclerotic carotids associated with enhanced serum antibodies, inflammation and apoptosis rate. Atherosclerosis. 2003; 168:153–162.
   PubMed Web of Science ®Google Scholar
• de Boer OJ, van der Wal AC, Becker AE. Atherosclerosis, inflammation, and infection. J Pathol. 2000; 190:237–243.
   PubMed Web of Science ®Google Scholar
• Jha HC, Vardhan H, Gupta R, Varma R, Prasad J, Mittal A. Higher incidence of persistent chronic infection of Chlamydia pneumoniae among coronary artery disease patients in India is a cause of concern. BMC Infect Dis. 2007; 7:48.
   PubMed Web of Science ®Google Scholar
• Bendtzen K, Hansen MB, Ross C, Svenson M. High avidity autoantibodies to cytokines. Trends Immunol Today. 1998; 19:209–211.
   PubMedGoogle Scholar
• Major AS, Fazio S, Linton MF. B-lymphocyte deficiency increases atherosclerosis in LDL receptor-null mice. Arterioscler Thromb Vasc Biol. 2002; 22:1892–1898.
   PubMed Web of Science ®Google Scholar
• Yamada T, Kakihara T, Kamishima T, Fukuda T, Kawai T. Both acute phase and constitutive serum amyloid A are present in atherosclerotic lesions. Patol Int. 1996; 46:797–800.
   PubMed Web of Science ®Google Scholar